Terumo Corporation
IFRS Financial Results for the Third Quarter of
the Fiscal Year Ending March 31, 2020

－1 －－2 －4. Consolidated Financial Statements① Consolidated Statements of Financial Position
As ofMarch 31, 2019

（Unit: Millions of yen）
As ofDecember 31, 2019

AssetsCurrent assets
Cash and cash equivalents

122,982

112,955

Trade and other receivables

128,462

138,566

Other current financial assets

1,744

921

Inventories

134,106

147,357

Other current assets

11,426

11,595

Total current assets

398,722411,395

Property, plant and equipment

201,986

253,152Goodwill and intangible assets

468,885

464,209

Non-current assets

Investments accounted for using theequitymethod
Other non-current financial assets

5,571

5,640

17,131

21,210

Deferred tax assets

24,62424,430

Other non-current assets

3,868

4,552

Total non-current assets

722,068

773,195

1,120,790

1,184,591

Total assets－3－

（Unit: Millions of yen）
As of
December 31, 2019

As ofMarch 31, 2019
Liabilities and Equity
Liabilities
Current liabilities
Trade and other payables

81,476

Bonds and borrowings

84,635
10,000

Other current financial liabilities

741

6,457

10,199

6,195

236

250

Other current liabilities

50,25850,890Total current liabilities

142,912

158,429

225,135

197,244

Other non-current financial liabilities

6,607

32,371

Deferred tax liabilities

24,302

23,679Defined benefit liabilities

12,823

11,8008888

Other non-current liabilities

10,807

9,442

Total non-current liabilities

279,764

274,628

422,677

433,057

Share capital

38,716

38,716

Capital surplus

52,02951,812

Treasury stock(32,381)(14,933)

Retained earnings

646,223

691,947

Other components of equity(6,553)(16,122)

698,034

751,41978

113

698,113751,533

1,120,790

1,184,591

Current tax liabilities
Provisions

Non-current liabilities
Bonds and borrowings

Provisions

Total liabilities
EquityTotal equity attributable to the owners of theparent
Non-controlling interests
Total equity
Total liabilities and equity－4－

② Consolidated Statements of Profit or Loss
For the nine months ended
December 31, 2018443,609
201,450
242,159
168,0376,629
2,277
78,474
1,621
4,985（Unit: Millions of yen）
For the nine months ended
December 31, 2019
470,144
211,509258,635
173,8443,593
2,134
86,250
1,424
2,091

(101)

(96)

75,00818,61356,39585,487
18,72566,762Attributable to:
Owners of the parent
Non-controlling interests
Total profit for the period

56,495(100)
56,39566,893(131)
66,762

Earnings per share
Basic earnings per share (yen)Diluted earnings per share (yen)

77.67
74.60

89.64
88.40

Revenue
Cost of sales
Gross profit
Selling, general and administrative expenses
Other income
Other expenses
Operating profit
Finance incomeFinance costs
Share of profit (loss) of investments accounted
for using the equity method
Profit before tax
Income tax expenses
Profit for the period－5－③ Consolidated Statements of Comprehensive Income

Profit for the period

For the nine months ended
December 31, 2018
56,395（Unit: Millions of yen）
For the nine months ended
December 31, 2019
66,762(433)

407

Other comprehensive income
Items that will not be reclassified to profit or loss
Changes in financial assets measured at fairvalue through other comprehensive income
Remeasurement of difined benefit plan(467)

Total items that will not be reclassified to profit orloss

(433)

(60)

20,475(10,163)

(258)

212

(58)

11

20,158(9,939)19,724(9,999)76,11956,763

Owners of the parent

76,22456,887

Non-controlling interests

(104)

(124)

76,11956,763

Items that are or may be reclassified subsequently
to profit or loss
Exchange differences on translation of foreign
operations
Cash flow hedges
Cost of hedging
Total items that are or may be reclassified
subsequently to profit or loss
Other comprehensive income/(loss) for the period
Total comprehensive income for the period
Attributable toTotal comprehensive income for the period(Note)

Items in the above statement are net of tax.

－6－

④ Consolidated Statements of Changes in Equity（Unit: Millions of yen）
Share capital
Balance at April 1, 2018
Change in the accounting
principles
Balance after the adjustment

38,716Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents ofsurplus
stock
earnings
equity52,445(101,546)

588,932

550,30754
38,71652,445(101,546)

588,986

Profit for the period

Total comprehensive income
Acquisition of treasury shares(6)

56,495

Disposal of treasury shares

155

(47)

Dividends(28,240)1

550,43554

550,361128

550,490

56,495(100)

56,395

19,72819,728(4)

19,724

19,72876,224(104)

76,119

(6)

(6)

00

(19,555)(19,555)(107)(19,555)

Transfer from other componentsof equity to retained earnings
Change in shares of subsidiaries
due to capital increas
Share-based payments

128

Total equity

54

56,495

Other comprehensive income

(1)
81
162

Conversion of convertible bonds
Total transactions with theowners of the Company
Balance at December 31, 2018(28,240)

Noncontrollinginterests

Total

38,716

81

162

162

65,06465,064(401)

66,116

(650)

(401)

66,264(20,252)53

45,66481

45,74652,044(35,281)625,229(8,458)672,250106672,356（Unit: Millions of yen）
Share capital
Balance at April 1, 2019

38,716Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents ofsurplus
stock
earnings
equity52,029(32,381)646,223

Profit for the period

Total comprehensive income
Acquisition of treasury shares

66,893(2)

Disposal of treasury shares

80(18)

Dividends

(101)

120

82

Conversion of convertible bonds(115)

17,250

(260)

(217)

17,448(21,170)

51,812(14,933)

691,947

Total transactions with theowners of the Company
Balance at December 31, 201978

66,893(131)

66,762(10,006) (10,006)

6(9,999)(124)

56,763(10,006)(61)(20,507)

Transfer from other componentsof equity to retained earnings
Change in shares of subsidiaries
due to capital increase
Share-based payments(467)

56,887－

7－

698,113

(2)

(2)

00

(20,507)(20,507)467
159

38,716

Total equity(6,553) 698,034

66,893

Other comprehensive income

Noncontrollinginterests

Total31437

159

132

132

16,874

16,874(3,502)

159(3,342)(16,122) 751,419

113

751,533

5. Segment information
Reportable segment information
Revenue and operating results of the reportable segments of the Group are described below.
For the third quarter of the fiscal year ended December 31, 2018
（Unit: Millions of yen）
Reportable Segments

Revenue
Revenue from sales
to external customers
Segment Profit(Adjusted operatingprofit)(Adjustment item）
Amortization ofintangible assets
acquired throughbusiness combinations
Non-recurring profit orloss (Note2)

Adjustments(Note1)

Amountrecorded on
consolidated
financialstatements

443,418

190

443,609

10,89591,240(60)

91,179(6,294)(11,134)

99(11,034)

Cardiac andVascularCompanyGeneral
HospitalCompany

Blood
Management
Company

240,957

125,869

76,59158,01522,328(4,839)Total(1,670)Operating profit

78,474

Finance income

1,621

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
methodPre-tax profit(4,985)(101)
75,008(Note) １．Amounts in ‘Adjustments’ are as follows:(1) ¥190 million adjustment to revenue from sales to external customers is mainly proceeds from outward
temporary staffing that is not attributable to reportable segments.
(2) ¥(60) million adjustment to segment profit consists of ¥(874) million for “inventories” and ¥813 million for“others”.
２．¥(1,670) million Non-recurring profit or loss mainly includes ¥1,111 million insurance revenue about
hurricane in Puerto Rico in 2017 and ¥(2,039) million for the change in fair value of contingent consideration
related to acquisition of Sequent Medical, Inc..

－8－

For the third quarter of the fiscal year ending March 31, 2020
（Unit: Millions of yen）
Reportable Segments

Revenue
Revenue from sales
to external customers
Segment Profit(Adjusted operatingprofit)（Adjustment item）
Amortization of
intangible assets
acquired throughbusiness combinations
Non-recurring profit orloss (Note2)

Adjustments(Note1)

Amountrecorded on
consolidated
financialstatements

469,976168

470,144

10,424

98,997(578)

98,419(6,153)(11,426)(440)(11,867)

Cardiac andVascularCompanyGeneral
HospitalCompany

Blood
ManagementCompany

263,473

127,786

78,71768,753

19,819(5,273)

Total

(300)

Operating profit

86,250Finance income

1,424

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
method(2,091)Pre-tax profit

85,487(96)(Note) １．Amounts in ‘Adjustments’ are as follows:(1) ¥168 million adjustment to revenue from sales to external customers is mainly proceeds from outward
temporary staffing that is not attributable to reportable segments.
(2) ¥(578) million adjustment to segment profit consists of ¥31 million for “inventories” and ¥(609) million for“others”.
２．¥(300) million Non-recurring profit or loss mainly includes ¥1,180 million insurance revenue about hurricane
in Puerto Rico in 2017 and ¥(1,099) million for business reorganization expenses.

－9－